全文获取类型
收费全文 | 567篇 |
免费 | 29篇 |
国内免费 | 22篇 |
专业分类
儿科学 | 34篇 |
妇产科学 | 4篇 |
基础医学 | 48篇 |
口腔科学 | 7篇 |
临床医学 | 79篇 |
内科学 | 98篇 |
皮肤病学 | 1篇 |
神经病学 | 7篇 |
特种医学 | 232篇 |
外科学 | 29篇 |
综合类 | 11篇 |
预防医学 | 19篇 |
眼科学 | 5篇 |
药学 | 29篇 |
肿瘤学 | 15篇 |
出版年
2024年 | 1篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 15篇 |
2017年 | 7篇 |
2016年 | 7篇 |
2015年 | 12篇 |
2014年 | 14篇 |
2013年 | 23篇 |
2012年 | 12篇 |
2011年 | 17篇 |
2010年 | 23篇 |
2009年 | 14篇 |
2008年 | 8篇 |
2007年 | 14篇 |
2006年 | 13篇 |
2005年 | 15篇 |
2004年 | 7篇 |
2003年 | 5篇 |
2002年 | 3篇 |
2001年 | 6篇 |
2000年 | 3篇 |
1999年 | 7篇 |
1998年 | 30篇 |
1997年 | 27篇 |
1996年 | 39篇 |
1995年 | 23篇 |
1994年 | 18篇 |
1993年 | 26篇 |
1992年 | 8篇 |
1991年 | 5篇 |
1990年 | 13篇 |
1989年 | 22篇 |
1988年 | 24篇 |
1987年 | 25篇 |
1986年 | 10篇 |
1985年 | 17篇 |
1984年 | 8篇 |
1983年 | 10篇 |
1982年 | 20篇 |
1981年 | 10篇 |
1980年 | 10篇 |
1979年 | 4篇 |
1978年 | 2篇 |
1977年 | 9篇 |
1976年 | 18篇 |
1975年 | 7篇 |
排序方式: 共有618条查询结果,搜索用时 15 毫秒
611.
Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients 总被引:1,自引:0,他引:1
Platelet transfusions from donors selectively mismatched for cross- reactive and certain non-cross-reactive HLA antigens were found to be more effective in HLA-A2 negative than in HLA-A2 positive, alloimmunized thrombocytopenic patients. The two groups of patients responded equally well to platelets matched for antigens of the HLA-A and B loci. Certain alloimmunized patients negative for HLA-A2 continued to respond satisfactorily to platelets selectively mismatched for non-cross-reactive HLA antigens as long as platelets containing HLA- A2 were avoided. The data indicate that platelet transfusion support can be provided within a broader range of donor-recipient HLA antigenic disparity to HLA-A2 negative alloimmunized patients than to those who are positive for this antigen. 相似文献
612.
血管内皮生长因子对佐剂性关节炎滑膜细胞基质金属蛋白酶3及基质金属蛋白酶9表达的影响 总被引:1,自引:0,他引:1
目的:观察血管内皮生长因子对佐剂性关节炎滑膜细胞质金属蛋白酶3及质金属蛋白酶9表达的影响,并探讨其意义。方法:实验于2006-02/12在桂林医学院实验中心完成。①实验材料:清洁级8周龄雄性Wistar大鼠6只,血管内皮生长因子为Peprotech EC LTD公司产品,基质金属蛋白酶3(扩增369bp)上游引物、下游引物,基质金属蛋白酶9(扩增405bp)上游引物、下游引物均购自晶美公司。②实验干预:先用弗氏完全佐剂造Wistar大鼠模型;造模20d后取Wistar大鼠右后足滑膜细胞进行原代培养。③实验分组:实验分为血管内皮生长因子组:取P2代细胞接种于6孔培养板,分别加入终浓度为5,25,50μg/L血管内皮生长因子;对照组:不加血管内皮生长因子。④实验评估:取病理切片观察滑膜细胞形态学改变;采用半定量反转录聚合酶链反应检测Wistar大鼠佐剂性关节炎滑膜细胞基质金属蛋白酶3及基质金属蛋白酶9的m-RNA表达。结果:①培养细胞的形态学观察:原代培养14d滑膜细胞从组织块边缘逸出,21d密集生长开始传代;传代细胞48h可明显分辨出树突样细胞、巨噬细胞样细胞和成纤维细胞样细胞;传至21代,细胞生长及特性稳定。②病理切片:滑膜组织有中性粒细胞、单核细胞、淋巴细胞浸润,滑膜细胞增生、排列紊乱,纤维素渗出,胶原纤维沉着,纤维素样坏死,呈滑膜炎表现。③基质金属蛋白酶3、基质金属蛋白酶9的mRNA表达:对照组基质金属蛋白酶3mRNA表达相对灰度值与血管内皮生长因子终浓度5,25,50μg/L组比较,差异有显著性意义(0.32±0.03,0.77±0.06,1.12±0.12,1.59±0.02,P<0.05);对照组基质金属蛋白酶9mRNA表达相对灰度值与血管内皮生长因子终浓度5,25,50μg/L组比较,差异有显著性意义(0.47±0.07,0.50±0.10,0.91±0.10,1.31±0.06,P<0.05);基质金属蛋白酶3和基质金属蛋白酶9mRNA表达随血管内皮生长因子浓度的加大表达增加。结论:血管内皮生长因子以剂量递增的方式对体外培养的佐剂性关节炎滑膜细胞基质金属蛋白酶3及基质金属蛋白酶9的表达有促进作用。 相似文献
613.
Ming Kai Lam Sali Al-Ansari Gooitzen M. van Dam René A. Tio Jan-Cees Breek Riemer H. J. A. Slart Jan-Luuk Hillebrands Clark J. Zeebregts 《Molecular imaging and biology》2013,15(3):250-261
Purpose
Unstable plaques may cause clinical events. Plaque destabilization results from the synergy between intraplaque angiogenesis and inflammation. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) are considered to be involved in these processes. We investigated the efficacy of the anti-VEGFR mimic single-chain VEGF (scVEGF) to map intra-plaque VEGFR expression and atherosclerotic plaque instability using near-infrared fluorescence (NIRF).Procedures
Human carotid plaques were retrieved from 15 symptomatic and five asymptomatic patients. NIRF plaque imaging was performed pre-/post-incubation with scVEGF/Cy5.5. Biopsies taken from regions with high (hot spot) and low (cold spot) NIRF signals were examined for VEGF-A, VEGFR-1 and VEGFR-2 mRNA expression levels using real-time RT-PCR analysis. Immunohistochemistry for CD31 (endothelium), CD68 (macrophages) and αSMA (smooth muscle cells) was performed to evaluate plaque composition.Results
NIRF imaging of 20 plaques revealed a heterogeneous distribution of scVEGF/Cy5.5 binding. After incubation NIRF activity increased from 3.9×10?5?±?5.2×10?6 to 3.0×10?4?±?2.2×10?5 and 5.8×10?5?±?1.9×10?5 to 3.1×10?4?±?1.9×10?5 photons/s/cm2/sr/illumination intensity on the intraluminal and extraluminal side, respectively (both p?<?0.001). Real-time RT-PCR analysis showed a ~1.2- and ~16.4-fold increased mRNA expression of VEGFR-1 and VEGFR-2, respectively, in hot spots (vs. cold spots). Immunohistochemistry exhibited higher intraplaque capillary density in hot spots (vs. cold spots) (17.2?±?3.7 vs. 5.4?±?2.2 capillary/mm2; p?=?0.037). Hot spots contained significantly reduced numbers of α-SMA-positive cells (vs. cold spots) (2.2?±?0.7 % vs. 6.9?±?1.5 %; p?=?0.038). Finally, a ~2-fold increase of CD68+ infiltrating macrophages within hot spots (vs. cold spots) was observed (not significant, p?=?0.17). Significant higher capillary density in hot spots (vs. cold spots) was observed in plaques from symptomatic patients but not in plaques from asymptomatic patients.Conclusion
Our data support that scVEGF/Cy5.5 is a suitable indicator for plaque instability and a promising diagnostic tool for risk assessment in cardiovascular diseases. 相似文献614.
Braun J Kästner P Flaxenberg P Währisch J Hanke P Demary W von Hinüber U Rockwitz K Heitz W Pichlmeier U Guimbal-Schmolck C Brandt A;MC-MTX./RH Study Group 《Arthritis and rheumatism》2008,58(1):73-81
OBJECTIVE: To compare the efficacy and safety of subcutaneous (SC) versus oral administration of methotrexate (MTX) in patients with active rheumatoid arthritis (RA). METHODS: MTX-naive patients with active RA (Disease Activity Score in 28 joints >or= 4) were eligible for the study if they had not previously taken biologic agents and had not taken disease-modifying antirheumatic drugs for 2 weeks prior to randomization. Patients were randomly assigned to receive 15 mg/week of MTX either orally (2 7.5-mg tablets plus a dummy prefilled syringe; n=187 patients) or SC (prefilled syringe containing 10 mg/ml plus 2 dummy tablets; n=188 patients) for 24 weeks. At week 16, patients who did not meet the American College of Rheumatology criteria for 20% improvement (ACR20) were switched from 15 mg of oral MTX to 15 mg of SC MTX and from 15 mg of SC MTX to 20 mg of SC MTX for the remaining 8 weeks, still in a blinded manner. The primary outcome was an ACR20 response at 24 weeks. RESULTS: At week 24, significantly more patients treated with SC MTX than with oral MTX showed ACR20 (78% versus 70%) and ACR70 (41% versus 33%) responses. Patients with a disease duration >or= 12 months had even higher ACR20 response rates (89% for SC administration and 63% for oral). In 52 of the ACR20 nonresponders (14%), treatment was switched at week 16. Changing from oral to SC MTX and from 15 mg to 20 mg of SC MTX resulted in 30% and 23% ACR20 response rates, respectively, in these patients. MTX was well tolerated. The rate of adverse events was similar in all groups. CONCLUSION: This 6-month prospective, randomized, controlled trial is the first to examine oral versus SC administration of MTX. We found that SC administration was significantly more effective than oral administration of the same MTX dosage. There was no difference in tolerability. 相似文献
615.
High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis 总被引:2,自引:2,他引:2
Straub RH; Zeuner M; Lock G; Scholmerich J; Lang B 《Rheumatology (Oxford, England)》1997,36(4):426-432
The aim was to determine serum levels of prolactin (PRL) and
dehydroepiandrosterone sulphate (DHEAS), and to demonstrate a link between
PRL or DHEAS and soluble immune mediators in patients with systemic
sclerosis (SSc) with different degrees of disease-induced organ
involvement. Thirty-one patients with SSc were studied to evaluate 18
possible disease manifestations. In the serum, PRL, DHEAS and soluble
immune mediators were determined by ELISA. Compared to SSc with <9
disease manifestations, patients with > or =9 disease manifestations had
higher PRL (P = 0.044), higher soluble interleukin 2 receptor (sIL-2R, P =
0.004) and vascular cell adhesion molecule (sVCAM, P = 0.044), and lower
DHEAS (P = 0.029). PRL (R(Rank) = 0.490, P = 0.003) and DHEAS (R(Rank) =
-0.399, P = 0.013) were significantly correlated with the number of disease
manifestations. The inverse correlation between PRL and DHEAS showed a
trend (P = 0.059). PRL correlated with sIL-2R (R(Rank) = 0.553, P = 0.001)
and sVCAM (R(Rank) = 0.520, P = 0.002). The number of disease
manifestations and sIL-2R correlated significantly (R(Rank) = 0.463, P =
0.006). Psychometric variables to examine the presence of depression were
not measured, but from the general aspect, the patients were not suffering
from major depression which may have influenced our results. In conclusion,
this study demonstrates the close association between DHEAS and,
particularly, PRL and SSc severity and T-lymphocyte mechanisms.
相似文献
616.
Coordinate glycosylation and cell surface expression of glycophorin A during normal human erythropoiesis 总被引:1,自引:2,他引:1
The expression of two epitopes on glycophorin A (GPA) during erythroid development was examined on normal human bone marrow using quantitative flow cytometry. The highly correlated binding of two monoclonal antibodies, one sensitive and the other insensitive to glycosylation, indicated that the two epitopes were coordinately expressed during erythroid development. Both antigens reached a maximum expression during the early normoblast stage and were maintained at a constant amount per cell throughout further maturation to erythrocytes. These data suggest that glycosylation of GPA, as detected by antibodies recognizing blood group (M) and (N) antigens, does not increase during erythroid maturation. 相似文献
617.
Kerst JM; Sanders JB; Slaper-Cortenbach IC; Doorakkers MC; Hooibrink B; van Oers RH; von dem Borne AE; van der Schoot CE 《Blood》1993,81(2):344-351
To study the receptors involved in the interaction between extracellular matrix proteins and hematopoietic progenitor cells, we analyzed the expression of beta 1 integrins on CD34+ bone marrow cells by means of immunoflowcytometry. Alpha 4 beta 1 and alpha 5 beta 1 were expressed, whereas alpha 1 beta 1, alpha 2 beta 1, alpha 3 beta 1, alpha 6 beta 1, and alpha v beta 1 were virtually absent. Furthermore, we assessed the alpha 4 and alpha 5 expression on committed myeloid progenitor cells. These colony-forming cells were detected in the alpha 4 dull fraction and the alpha 5 dull fraction. During myeloid differentiation, both in vivo and in vitro, a differential expression of alpha 4 beta 1 and alpha 5 beta 1 was observed. alpha 5 beta 1 was found to be lost at the myelocytic-metamyelocytic stage, before the loss of alpha 4 beta 1, at the band stage. Functional studies showed no binding of erythroid progenitor-depleted, CD34+ bone marrow cells to fibronectin. However, protein kinase C activation strongly induced fibronectin binding (68% of the cells). Inhibition experiments with specific antibodies and peptides showed the binding to be mediated by both alpha 4 beta 1 and alpha 5 beta 1. Also, colony-forming cells of granulocytes and macrophages were demonstrated to adhere to fibronectin in an activation-dependent way. During granulocyte colony-stimulating factor-induced in vitro maturation, the activation-dependent fibronectin binding capacity is gradually lost. We conclude that: (1) CD34+ bone marrow cells express alpha 4 beta 1 and alpha 5 beta 1; (2) the expression of alpha 4 beta 1 and alpha 5 beta 1 is differentially expressed during myeloid differentiation; and (3) binding of CD34+ bone marrow cells to fibronectin is activation dependent. 相似文献
618.
Goldman JM; Szydlo R; Horowitz MM; Gale RP; Ash RC; Atkinson K; Dicke KA; Gluckman E; Herzig RH; Marmont A 《Blood》1993,82(7):2235-2238
We analyzed the outcome of 450 HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in chronic phase performed between 1985 and 1990 and reported to the International Bone Marrow Transplant Registry (IBMTR). All patients received either hydroxyurea (n = 292) or busulfan (n = 158) to treat their CML before transplant. The median interval between diagnosis and transplant was 10 months (range, 1 to 191). Patients treated with hydroxyurea had a higher probability (95% confidence interval) of leukemia-free survival (LFS) at 3 years than those treated with busulfan (61% [51% to 70%] v 45% [36% to 55%], P < .0003). Probability of LFS was also higher in patients transplanted within 1 year of diagnosis (61% [53 to 68%] v 47% [38% to 57%], P < .001). After adjustment for patient and transplant covariables in a multivariate analysis, prior chemotherapy and duration of disease pretransplant were independently associated with LFS. These data support the use of hydroxyurea rather than busulfan and transplant within 1 year of diagnosis for patients with CML and an HLA-identical sibling. 相似文献